NuSep

Redefining BioSeparations

Investor Presentation

21st May 2010

Important Notice

This presentation is not and does not form part of any offer, invitation or recommendation in respect of securities. Any decision to buy or sell NuSep securities or other products should be made only after seeking appropriate financial advice. Reliance should not be placed on information or opinions contained in this presentation and subject only to any legal obligation to do so, the Company does not accept any obligation to correct or update them. This presentation does not take into consideration the investment objectives, financial situation or particular needs of any particular investor.

To the fullest extent permitted by law, NuSep and its affiliates and their respective officers, directors, employees and agents, accept no responsibility for any information provided in this presentation, including any forward looking information, and disclaim and liability whatsoever (including for negligence) for any loss howsoever arising from any use of this presentation or reliance on anything contained in or omitted from it or otherwise arising in connection with this.

Our New Logo

What is NuSep?

NuSep is a Life Science Toolbox Company that develops products for the:

- Proteomics and
- IVF markets

BioInquire is a profitable software company whose products enhance NuSep's products.

NuSep’s Product Markets



The BioInquire acquisition addresses the Mass Spec market

ProteomeSep

BioInquire Website

ProteoIQ provides customers with a 'Google' for proteins

Fractions to Functions



BioMarker Identification



ProteoIQ Analysis



ProteoIQ peptide Analysis



ProteoIQ Version 2 – Significant Upgrade

- To be launched at the American Society for Mass Spectrometry, 23 May 2010
- ProteoIQ version 2 enables this software to address the entire $130m proteomics software market.
- Major upgrade offering a number of unique features including cross platform data handling and data volume capabilities

From a User

"ProteoIQ has fundamentally changed how we process, interpret, and share data within our lab and between collaborators. The software has become an indispensable tool in our proteomics workflows and the technical support from BioInquire is second to none. Outstanding product!"

David Muddiman and Adam Hawkridge, from the W.M. Keck FT-ICR Mass Spectrometry Laboratory, NC State University.

ηUView Gels for Educators

- NuSep has finalised a distribution agreement for the sale of its ηUView gels in kits for US high school and college educators
- Using gels with ηUView technology students are able to run & visualise results inside a normal laboratory class.
- Possible US market of $800,000



SpermSep Update

- First clinical trial conducted by Westmead Fertility Centre completed 2008
- 3 out of 9 women have fallen pregnant with 3 live births to date
- New SpermSep Cartridge Patent lodged
- Disposable cartridge/ Cross contamination issues addressed
- Further Clinical trials to be completed by Dec 2010
- Applications in the veterinary field. Projects with two Australian Universities

Positives from BioInquire Acquisition

- BioInquire is an EPS Positive Acquisition
- Products are synergistic with NuSep products
- Expansion in sales force and product synergies will drive sales of ProteomeSep and Gels
- Expansion of Sales Force in the US and Australia

Deal Structure

NuSep will acquire BioInquire for 3 times its 2010 Profit.

NuSep will pay for this by:

- Pay US$1.5m upon NuSep shareholder approval in March 2010;
- Issue US$500,000 in NuSep shares on 31 December 2010;
- Pay up to US$1m on 31 December 2010 subject to achievement of budgeted profit target;
- Pay balance of 3 times 2010 profit on 30 June 2011

The deal is structured to incentivise BioInquire to exceed the budgeted profit of US$1.2m

1:2 Rights Issue -Terms

- 1:2 Entitlement
- Free 35¢ Listed Share Option, expiring 1 Sep 12 on a 1:3 basis
- $3m underwritten by Board and Significant Shareholders
- Closes Friday 21 May 2010

Use of Funds

- $1.7m (US$1.5m) to acquire BioInquire
- $1m to complete clinical trials of SpermSep
- $0.2m fund raising costs
- Over subscription for working capital

FY 2011 Forecast – Revised for BioInquire

	30 June 2011
Revenue	$6.5m
Gross Margin	$4.8m
Net Profit	**$1.8m**

FY 2010 Forecast – Earnings Per Share



Earnings Per Share for the year ended 30 June 2010
Increase from 2¢ per share to 3.6¢ per share post the acquisition

NuSep - A Company with a bright future

- **Intellectual Property** - extensive intellectual property estate – New high margin products
- **Distribution Network -** both direct and OEM global distribution – Fast launch of new products
- **Focus on Direct sales and Marketing**
- **Blue Sky –** Australian IVF market – $4.5 million dollars in sales
- **Niche Player** - niche player in the life science market – Can dominate selected markets

NuSep